Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$122.30
-1.00 (-0.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $359.1M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.4B
P/E
37.3x
↑EV/EBITDA
25.6x
↑ROE
25.3%
↑Gross Margin
73.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.7%
FCF CAGR
+0.2%
FCF margin
19.7%
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.54B · net income $332.8M · FCF $303.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.54B | $1.54B | $1.42B | $1.30B | $1.10B |
| Net Income | $332.8M | $332.8M | $351.4M | $365.4M | $373.8M |
| EBITDA | $451.9M | $451.9M | $474.8M | $494.9M | $476.9M |
| EPS | 3.29 | 3.29 | 3.48 | 3.62 | 3.70 |
| Gross Margin | 73.4% | 73.4% | 72.4% | 73.3% | 72.6% |
| Operating Margin | 29.4% | 29.4% | 28.8% | 34.0% | 30.3% |
| Net Margin | 21.6% | 21.6% | 24.7% | 28.2% | 33.9% |
| Balance Sheet | |||||
| Current Ratio | 4.94 | 4.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $303.0M | $303.0M | $359.1M | $377.3M | $300.8M |
| Returns | |||||
| ROE | 25.3% | 25.3% | 20.4% | 18.0% | 19.0% |
| Valuation | |||||
| P/E | 37.29 | 37.29 | 31.78 | 28.26 | 23.17 |
| EV/EBITDA | 25.60 | 25.60 | 20.97 | 17.75 | 15.03 |
| P/B | 9.41 | 9.41 | 6.48 | 5.09 | 4.39 |
| Growth & Yield | |||||
| Revenue Growth | 8.1% | 8.1% | 9.7% | 17.4% | — |
| EPS Growth | -5.5% | -5.5% | -3.9% | -2.2% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
48.9%
EPS terminal req.
$10.85
Spread vs growth
-54.3%
5Y implied EPS CAGR
31.9%
EPS terminal req.
$13.13
Spread vs growth
-37.4%
10Y implied EPS CAGR
20.4%
EPS terminal req.
$21.15
Spread vs growth
-25.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.8%
Start / end P/E
28.5x → 37.2x
EPS bridge
3.48 → 3.29
Residual
-1.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.